← Eichor
Condition: Neuroendocrine Carcinoma Of Lung Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Carcinoma Of Lung

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07429851Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
NA · 1 location(s) · Goethe University · NCT07161310A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987The Florida ASCENT Study
NA · 1 location(s) · University of Florida · NCT07042243At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05878964Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NA · 2 location(s) · Nantes University Hospital · NCT06735560Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309BostonGene and Exigent Genomic INsight Study
Phase N/A · 7 location(s) · BostonGene · NCT06272864Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Phase 2 · 4 location(s) · CNAO National Center of Oncological Hadrontherapy · NCT05229614Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Phase N/A · 1 location(s) · Washington University School of Medicine · NCT04354064Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Phase 1 · 3 location(s) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · NCT06424665A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT05978284A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06936735Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Mela
Phase 3 · 15 location(s) · ETOP IBCSG Partners Foundation · NCT05522660A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Ot
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06505824Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Phase 1 · 3 location(s) · Washington University School of Medicine · NCT06529822
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.